41 Results for "

GIP receptor

" in MedChemExpress (MCE) Product Catalog:
Products (41)

41 Results for "GIP receptor" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P10138
CAS No.: 1884226-05-4
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

Human GIP(3-30), amide is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide has potential anti-obesity and anti-diabetic effects .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P10138A
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

Human GIP(3-30), amide TFA is the TFA salt form of human GIP(3-30), amide (HY-P10138). Human GIP(3-30), amide TFA is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide TFA has potential anti-obesity and anti-diabetic effects .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P2541A
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P3255
CAS No.: 2315504-40-4
DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways .
loading...
    loading...
Cat. No.: HY-164535
CAS No.: 2887445-76-1
Synonyms: AMG 133
Maridebart cafraglutide (AMG 133) is a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonist with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. Maridebart cafraglutide shows antagonist activity against human, cynomolgus monkey and rat GIPR with IC50 values of 46.4 nM, 26.5 nM, 822.3 nM, respectively. Maridebart cafraglutide shows agonist activity against human, cynomolgus monkey, rat and mouse GLP-1R with EC50 values of 24.4 pM, 5.7 pM, 2.4 pM and 123 pM, respectively. Maridebart cafraglutide can be used for the study of obesity and type 2 diabetes .
loading...
    loading...
Cat. No.: HY-P3247
CAS No.: 444073-04-5
Target:  

Insulin Receptor

[D-Ala2]-GIP (human) is a GIP receptor agonist (EC50 = 630 pM). [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP (HY-W114750)-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc
loading...
    loading...
Cat. No.: HY-P2542
CAS No.: 1802086-25-4
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo .
loading...
    loading...
Cat. No.: HY-P10735
CAS No.: 181591-59-3
Synonyms: Gastric inhibitory polypeptide(mouse); GIP(1-42) (mouse)
Target:  

Lipase Apoptosis

Research Areas:  

Metabolic Disease

GIP (Gastric inhibitory polypeptide) (mouse) is a gastrointestinal hormone that is secreted by the intestinal K cells, and also expressed in and secreted from pancreatic islets. GIP (mouse) promotes insulin secretion from pancreatic β cells via the G-protein-coupled GIP receptor (GIPR). GIP (mouse) promotes pancreatic β cell proliferation and inhibits apoptosis. GIP (mouse) also exerts direct lipogenic effects on adipose tissue .
loading...
    loading...
Cat. No.: HY-P10959
CAS No.: 2923558-68-1
Synonyms: LY3532226
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

Macupatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide improves insulin secretion responses and insulin sensitivity.Macupatide can be used for the research of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-P1434
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

[Pro3]-GIP (mouse) is a GIP receptor antagonist (IC50: 2.6 μM). [Pro3]-GIP (mouse) improves glucose tolerance and insulin sensitivity in ob/ob mice. [Pro3]-GIP (mouse) can be used for research of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-P11271
CAS No.: 2940971-65-1
Research Areas:  

Metabolic Disease

Ribupatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
loading...
    loading...
Cat. No.: HY-P10929
CAS No.: 2460751-66-8
Target:  

Drug Intermediate

Research Areas:  

Others

Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH is a drug intermediate in the synthesis of Tirzepatide. Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist .
loading...
    loading...
Cat. No.: HY-P10302A
Target:  

GLP Receptor

GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC50 of 0.57 nM for GLP-1R and an EC50 of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .
loading...
    loading...
Cat. No.: HY-153476
CAS No.: 2807481-02-1
Target:  

GCGR GLP Receptor

Research Areas:  

Inflammation/Immunology

GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
loading...
    loading...
Cat. No.: HY-153476A
Target:  

GLP Receptor GCGR

Research Areas:  

Inflammation/Immunology

GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
loading...
    loading...
Cat. No.: HY-P10959A
Synonyms: LY3532226 acetate
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

Macupatide acetate is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide acetate improves insulin secretion responses and insulin sensitivity.Macupatide acetate can be used for the research of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-P3584A
Synonyms: (Pro3) Gastric Inhibitory Peptide, human TFA
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

(Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with Ki/ Kd value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes .
loading...
    loading...
Cat. No.: HY-P5390A
Research Areas:  

Metabolic Disease

GIP, rat TFA is a bioactive peptide derived from rats. GIP, rat TFA inhibits GIP-mediated postprandial insulin release as well as GIP-promoted glucose uptake in the upper small intestine. GIP, rat TFA can be used in research related to insulin resistance, glucose intolerance, and type 2 diabetes .
loading...
    loading...
Cat. No.: HY-P10591
CAS No.: 2675496-01-0
Synonyms: Olatorepatidum; HS-20094
Research Areas:  

Metabolic Disease

Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect .
loading...
    loading...
Cat. No.: HY-P11271A
Research Areas:  

Metabolic Disease

Ribupatide TFA is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Ribupatide TFA can be studied in antidiabetic research .
loading...
    loading...